Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as beta2-adrenoceptor agonists.

Bioorg Med Chem Lett

Department of Chemical Research, Boehringer Ingelheim Pharma GmbH & Co KG, 88397 Biberach, Germany.

Published: December 2009

Novel beta(2)-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the beta(2)-adrenoceptor with a high beta(1)/beta(2)-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the beta(2)-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5h.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bmcl.2009.10.013DOI Listing

Publication Analysis

Top Keywords

5-hydroxy-4h-benzo[14]oxazin-3-ones beta2-adrenoceptor
4
beta2-adrenoceptor agonists
4
agonists novel
4
novel beta2-agonists
4
beta2-agonists 5-hydroxy-4h-benzo[14]oxazin-3-one
4
5-hydroxy-4h-benzo[14]oxazin-3-one moiety
4
moiety head
4
head group
4
group described
4
described systematic
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!